{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:43:10Z","timestamp":1770997390159,"version":"3.50.1"},"reference-count":28,"publisher":"The Society for Antibacterial and Antifungal Agents, Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biocontrol Sci."],"published-print":{"date-parts":[[2012]]},"DOI":"10.4265\/bio.17.121","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T22:30:32Z","timestamp":1348266632000},"page":"121-128","source":"Crossref","is-referenced-by-count":18,"title":["Cell Viability Score as an Integrated Indicator for Cytotoxicity of Benzalkonium Chloride-Containing Antiglaucoma Eyedrops"],"prefix":"10.4265","volume":"17","author":[{"given":"MASAHIKO","family":"AYAKI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ATSUO","family":"IWASAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSHIMI","family":"NIWANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2789","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Ammar, D. A., Noecker, R. J., and Kahook, M.Y. (2011) Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. <I>Adv. Ther<\/I>., <B>28<\/B>, 501-510.","DOI":"10.1007\/s12325-011-0029-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Asada, H., Takaoka-Shichijo, Y., Nakamura, M., and Kimura, A. (2010) Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy. <I>Yakugaku Zasshi<\/I>, <B>130<\/B>, 867-871. in Japanese.","DOI":"10.1248\/yakushi.130.867"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Ayaki, M., and Iwasawa, A. (2010) . Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. <I>Clin. Ophthalmol<\/I>., <B>4<\/B>, 919-924.","DOI":"10.2147\/OPTH.S13406"},{"key":"4","unstructured":"Ayaki, M., and Iwasawa, A. (2011b) Critical concentration of benzalkonium chloride in eye drop for toxicity in cultured ocular surface cell lines. <I>Inv. Ophthalmol. Vis. Sci<\/I>., <B>52<\/B>, E-Abstract 1955."},{"key":"5","unstructured":"Ayaki, M, Yaguchi, S, Iwasawa, A,, and Koide, R. (2011c) Cytotoxicity of six ophthalmic solutions containing carteolol for four cultured corneal and conjunctival cell lines. <I>Folia Japonica de Ophthalmologica Clinica<\/I>. (in Japanese) , <B>4<\/B>, 348-354."},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"7","unstructured":"Boyle, J.E., Ghosh, K., Gieser, D.K., and Adamsons, I.A. (1998) A randomized trial comparing the dorzolamide\/timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. <I>Ophthalmology<\/I>, <B>105<\/B>, 1945-1951."},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1080\/02713680801971857"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Craven, E. R., Walters, T. R., Williams, R., Chou, C., Cheetham, J. K., and Schiffman, R. ; Combigan Study Group. (2005) Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. <I>J. Ocul. Pharmacol. Ther<\/I>., <B>21<\/B>, 337-348.","DOI":"10.1089\/jop.2005.21.337"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Feghhi, M., Mahmoudabadi, A. Z., and Mehdinejad, M. I. (2008) Evaluation of fungal and bacterial contaminations of patient-used ocular drops. <I>Med. Mycol<\/I>., <B>46<\/B>, 17-21.","DOI":"10.1080\/13693780701487979"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Fudemberg, S.J., Batiste, C., and Katz, L. J. (2008) Efficacy, safety, and current applications of brimonidine. <I>Expert Opin. Drug Saf<\/I>., <B>7<\/B>, 795-799. Review.","DOI":"10.1517\/17425250802457609"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(01)00246-6"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0776"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kim, M. S., Choi, C. Y., Kim, J. M., Chang, H. R., and Woo, H. Y (2008) Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. <I>Br. J. Ophthalmol<\/I>., <B>92<\/B>, 1518-1521.","DOI":"10.1136\/bjo.2008.144469"},{"key":"15","unstructured":"Kitazawa, Y., Smith, P., Sasaki, N., Kotake, S., Bae, K., and Iwamoto, Y. (2011) Travoprost 0.004%\/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, double-masked comparison of safety and efficacy. <I>Eye (Lond.) <\/I>, <B>25<\/B>, 1161-1169."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Liang, H., Baudouin, C., Pauly, A., and Brignole-Baudouin, F. (2008) Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. <I>Br. J. Ophthalmol<\/I>., <B>92<\/B>, 1275-1282.","DOI":"10.1136\/bjo.2008.138768"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Liang, H., Brignole-Baudouin, F., Pauly, A., Riancho, L., and Baudouin, C. (2011a) Polyquad-preserved travoprost\/timolol, benzalkonium chloride (BAK) -preserved travoprost\/timolol, and latanoprost\/timolol in fixed combinations: a rabbit ocular surface study. <I>Adv. Ther<\/I>., <B>28<\/B>, 311-325.","DOI":"10.1007\/s12325-011-0003-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Liang, H., Pauly, A., Riancho, L., Baudouin, C., and Brignole-Baudouin, F. (2011b) Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. <I>Br. J. Ophthalmol<\/I>., <B>95<\/B>, 869-875.","DOI":"10.1136\/bjo.2010.189449"},{"key":"19","unstructured":"Motolko, M. A. (2008) Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. <I>Curr. Med. Res. Opin<\/I>., <B>24<\/B>, 2663-2667."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Miglior, S., Grunden, J. W., and Kwok, K., Xalacom\/Cosopt European Study Group. (2010) Efficacy and safety of fixed combinations of latanoprost\/timolol and dorzolamide\/timolol in open-angle glaucoma or ocular hypertension. <I>Eye (Lond) <\/I>, <B>24<\/B>, 1234-1242.","DOI":"10.1038\/eye.2009.307"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Pellinen, P. and Lokkila, J. (2009) Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. <I>Ophthalmic. Res<\/I>., <B>41<\/B>, 118-122.","DOI":"10.1159\/000192082"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Rahman, M. Q., Tejwani, D., Wilson, J. A., Butcher, I., and Ramaesh, K. (2006) Microbial contamination of preservative free eye drops in multiple application containers. <I>Br. J. Ophthalmol<\/I>., <B>90<\/B>, 139-141.","DOI":"10.1136\/bjo.2005.078386"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Ryan, G. Jr, Fain, J. M., Lovelace C., and Gelotte K. M. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chlorides and travoprost with the sofZia preservative system. <I>BMC Ophthalmol<\/I>., 2011 Apr 21;11, 8.","DOI":"10.1186\/1471-2415-11-8"},{"key":"24","unstructured":"Strohmaier, K., Snyder, E., DuBiner, H., and Adamsons, I. (1998) The efficacy and safety of the dorzolamide\/timolol combination versus the concomitant administration of its components. Dorzolamide\/Timolol Study Group. <I>Ophthalmology<\/I>, <B>105<\/B>, 1936-1944."},{"key":"25","unstructured":"Tali, H., and Coar, G. (2001) Microbial contamination of eye drops. <I>Cent. Eur. J. Public. Health<\/I>, <B>9<\/B>, 162-164."},{"key":"26","doi-asserted-by":"crossref","unstructured":"Uematsu, M., Kumagami, T., Shimoda, K., Kusano, M., Teshima, M., To, H., Kitahara, T., Kitaoka, T., and Sasaki, H. (2011) Polyoxyethylene hydrogenerated cater oil modulates benzalkonium chloride toxicity: Comparison of acute corneal barrier dysfunction induced by travoprostZ and travoprost. <I>J. Ocul. Pharmacol. Ther<\/I>., <B>27<\/B>, 437-444","DOI":"10.1089\/jop.2010.0175"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Uusitalo, H., Kaarniranta, K., and Ropo, A. (2008) Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.<I> Acta. Ophthalmol. Suppl. (Oxf.) <\/I>, <B>242<\/B>, 7-13.","DOI":"10.1111\/j.1755-3768.2008.01380.x"},{"key":"28","unstructured":"Yamaguchi, D., Ayaki, M., Yaguchi, S., Iwasawa, A., and Koide, R. (2010) Cytotoxicity of four ophthalmic solutions containing nipradilol for three corneal and one conjunctival cell lines. <I>Folia Japonica de Ophthalmologica Clinica<\/I> (in Japanese) , <B>3<\/B>, 1245-1249."}],"container-title":["Biocontrol Science"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:36:08Z","timestamp":1621539368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bio\/17\/3\/17_121\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4265\/bio.17.121","relation":{},"ISSN":["1342-4815","1884-0205"],"issn-type":[{"value":"1342-4815","type":"print"},{"value":"1884-0205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}